A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs GSK 3377794 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Aug 2019 Planned End Date changed from 1 Jul 2021 to 2 Jul 2021.
- 13 Aug 2019 Planned primary completion date changed from 1 Jul 2021 to 2 Jul 2021.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research.